Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

The Economic and Health Utilization Cost of Clinically Significant Cytomegalovirus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation

Michelle K Yong, MBBS, FRACP, MPH, PhD, Shio Yen Tio, MBBS, FRACP, Jake Valentine, BBioMedSc, Joe Sasadeusz, MBBS FRACP PhD, Lynette C.Y. Chee, Ashish Bajel, MBBS, FRACP, FRCPA, David Ritchie, MD PhD, Monica Slavin, MBBS FRACP

Blood (2019) 134 (Supplement_1): 3437.

https://doi.org/10.1182/blood-2019-128227

Published: 2019

Journal Articles

Efficacy of Artesunate for Treatment of Cytomegalovirus Reactivations in Allogeneic Haematopoietic Stem Cell Transplant Recipients Who Are Intolerant/Unsuitable for Ganciclovir Therapy

Ramnath K Shenoy, MD, Anant Gokarn, MD, Anup Toshniwal, MDDM, Siddhesh Arun Kalantri, MD, Akanksha Chichra, DNB, Sachin Punatar, MBBS,MDDM MDcal Oncology, Avinash Bonda, MD DM, Lingaraj Nayak, MDDM MDcal Oncology, Libin J Mathew, Vivek Bhat, MD, Sanjay Biswas, MD, Rohini Kelkar, MD, Navin Khattry, MD DM MDcal Oncology

Blood (2019) 134 (Supplement_1): 4506.

https://doi.org/10.1182/blood-2019-128766

Published: 2019

Journal Articles

Increased Incidence of Viral Reactivation after T Cell Replete Haploidentical Stem Cell Transplantation in Association with Delayed Immune Reconstitution

Ioannis Tsonis, MD, Dimitrios Karakasis, MD, Maria Bouzani, MD, Chara Giatra, MD, Zois Mellios, MD, Georgia Tounta, MD, Tatiana Tzenou, MD, Dimitra Oikonomopoulou, MD, Eirini Grispou, Maria Katsareli, Maria-Eleni Karatza, Kimon Fountoulis, MD, Themistoklis Karmiris, MD, Stavros Gigantes, MD, Ioannis Baltadakis, MD

Blood (2019) 134 (Supplement_1): 4511.

https://doi.org/10.1182/blood-2019-131127

Published: 2019

Journal Articles

The Efficacy and Safety of Cidofovir in Salvage Therapy for CMV Infection in the Patients with Haploid Hematopoietic Stem Cell Transplantation

Guo-Pan Yu, MD, Zhao Yin, Zhiping Fan, Fen Huang, Na Xu, Ling Jiang, Zhixiang Wang, PhD, Li Xuan, MD, Qifa Liu, MD, Ru Feng, MD, Jing Sun

Blood (2019) 134 (Supplement_1): 5659.

https://doi.org/10.1182/blood-2019-126705

Published: 2019

Journal Articles

Letermovir Prophylaxis Is Effective for Cytomegalovirus Reactivation after Allogeneic Hematopoietic Cell Transplantation: Single Center Real-World Data

Patrick Derigs, MD, Maria-Luisa Schubert, MD, Paul Schnitzler, PhD, Carsten Müller-Tidow, MD, Thomas Luft, MD PhD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 5650.

https://doi.org/10.1182/blood-2019-125675

Published: 2019

Journal Articles

ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience

Blood (2018) 132 (Supplement 1): 3381.

https://doi.org/10.1182/blood-2018-99-110252

Published: 2018

Journal Articles

Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function

Yevgeniya Foster, MD, Michael J Grant, MD, Samantha M Thomas, MS, Blake Cameron, MD MBI, Doug Raiff, PharmD, BCPS, Kelly Corbet, B.S., Christopher Ferreri, MD, Mitchell E. Horwitz, MD

Blood (2018) 132 (Supplement 1): 4594.

https://doi.org/10.1182/blood-2018-99-113189

Published: 2018

Journal Articles

A Step Forward Towards Cytomegalovirus Free Hematopoietic Stem Cell Transplantation

Alfaraj Abeer, MBBS, Daniel R Reed, MD, Gina Petroni, PhD, Sandra Monson, PhD, Paige Williams, Kathlene DeGregory, PharmD, BCOP, Leonid Volodin, MD, Tamila L Kindwall-Keller, DO, Karen K. Ballen, MD

Blood (2018) 132 (Supplement 1): 5708.

https://doi.org/10.1182/blood-2018-99-117068

Published: 2018

Journal Articles

Post Transplant Prophylaxis with High Dose Valacyclovir through Day 100 Versus Day of Post Transplant Hospital Discharge Decreases Cytomegalovirus Reactivation in Adult Umbilical Cord Blood Transplant Recipients

Prashant Sharma, MD, Jennifer MacDonald, Jeff Kaiser, Jennifer Tobin, Matthew Miller, Maheen Abidi, MD, Esther Benamu, MD, Enkhtsetseg Purev, MD PhD, Bradley M. Haverkos, MD MPH, MS, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 4659.

https://doi.org/10.1182/blood-2018-99-110211

Published: 2018

Journal Articles

Prospective Study of High Dose Foscarnet Prophylaxis for HHV-6 Related CNS Diseases in Cord Blood Transplantation for Adult Patients

Kazuya Ishiwata, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Aya Nishida, MD, Daisuke Kaji, MD, Shinsuke Takagi, Hisashi Yamamoto, MD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Atsushi Wake, MD PhD, Akiko Yoneyama, MD PhD, Shigeyoshi Makino, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2017) 130 (Supplement 1): 3223.

https://doi.org/10.1182/blood.V130.Suppl_1.3223.3223

Published: 2017

Journal Articles

CMV Reactivation Post CD34+ Selected Allo-HCT Has Adverse Outcomes on Blood Counts Recovery

Roni Tamari, MD, Christina Cho, MD, Patrick Hilden, MS, Taylor Borrill, BA, CCRP, Molly Maloy, MS, H.R. Castro-Malaspina, MD, Esperanza B. Papadopoulos, MD, Ann A. Jakubowski, MD PhD, Genovefa Papanicolaou, Sergio A. Giralt, MD, Miguel-Angel Perales, MD

Blood (2017) 130 (Supplement 1): 3319.

https://doi.org/10.1182/blood.V130.Suppl_1.3319.3319

Published: 2017

Journal Articles

BK Virus Induced Haemorrhagic Cystitis in Haematopoietic Stem Cell Transplant Setting — a 10 Year Retrospective Case Control Study

Asha Mary Abraham, MBBS, MD PhD, Sharon Lionel, Anu Korula, MBBS, MD DM, Anup Devasia, Nisham PN, Kulkarni Uday Prakash, Kavitha M Lakshmi, MSc, Aby Abraham, MD DM, Alok Srivastava, MD, Vikram Mathews, MD DM, Biju George, MDDM

Blood (2017) 130 (Supplement 1): 5470.

https://doi.org/10.1182/blood.V130.Suppl_1.5470.5470

Published: 2017

Journal Articles

Use of Leflunomide for Treatment of Cytomegalovirus Infection in Recipients of Allogeneic Stem Cell Transplant

Anant Gokarn, MD, Anup Toshniwal, MD, Amogh Pathak, MBBS, Sankalp Arora, MBBS, Avinash Bonda, MD DM, Pankaj Dwivedi, MD, Sachin Punatar, MD DM, Vivek Bhat, MD, Sanjay Biswas, MD, Rohini Kelkar, MD, Tapan Saikia, MD, Sadhana Kannan, MSc, Navin Khattry, MD DM

Blood (2017) 130 (Supplement 1): 1945.

https://doi.org/10.1182/blood.V130.Suppl_1.1945.1945

Published: 2017

Journal Articles

HHV-6 Prophylaxis with Foscanet Improves Hematopoietic Engraftment after Umbilical Cord Blood Transplantation

Nelli Bejanyan, MD, John Rogosheske, PharmD, Todd E. DeFor, MS, Jaime Green, MD, Troy C Lund, MD PhD, Daniel J. Weisdorf, MD, John E. Wagner, MD, Claudio G Brunstein, MD PhD

Blood (2017) 130 (Supplement 1): 1951.

https://doi.org/10.1182/blood.V130.Suppl_1.1951.1951

Published: 2017

Journal Articles

3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood

Emily Blyth, Barbara Withers, Leighton Edward Clancy, PhD, Agnes S. M. Yong, MDPhD, Christopher Fraser, MD, Jane Burgess, Renee Simms, Gloria Castellano Gonzalez, PhD, David Kliman, MBBS, Ming-Celine Dubosq, MD, David Bishop, Gaurav Sutrave, MBBS,, Chun Kei Kris Ma, PhDMBBS, Peter J. Shaw, MA,FRACP, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1919.

https://doi.org/10.1182/blood.V130.Suppl_1.1919.1919

Published: 2017

Journal Articles

Analysis of Anti-CMV T-Cell Immunity and CMV Reactivation after Allogeneic Hematopoietic Cell Transplantation

George Chen, MD, Yali Zhang, MS, Joseph Dennis Tario, PhD, Amanda Herko Przespolewski, MD, Dalin Pan, Patrick Mellors, MD, Christine Ho, MD, Sophia R. Balderman, MD, Maureen Ross, MD PhD, Liselotte Brix, PhD, Paul K. Wallace, MS,PhD, Philip L. McCarthy, MD, Theresa Hahn, PhD

Blood (2017) 130 (Supplement 1): 4496.

https://doi.org/10.1182/blood.V130.Suppl_1.4496.4496

Published: 2017

Journal Articles

Donor-Derived Marrow Mesenchymal Stem Cells Co-Transplantation Following Haploidentical Hematopoietic Stem Cell transplantation: a Multicenter Clinical Study in 35 Severe Aplastic Anemia Children

Zhenkun Wang, PhD, Limin Li, MD, Hongjuan Yu, PhD, Fenglin Cao, MD PhD, Yang Xiao, MD, Zenghui Liu, MD, Ce Shi, MD PhD, Zhiyu Liu, MD, Weijia Feng, MD, Xiaolong Liu, Jin Zhou

Blood (2017) 130 (Supplement 1): 4482.

https://doi.org/10.1182/blood.V130.Suppl_1.4482.4482

Published: 2017

Journal Articles

How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients

Firas El Chaer, Dimpy P. Shah, Roy F. Chemaly

Blood (2016) 128 (23): 2624–2636.

https://doi.org/10.1182/blood-2016-06-688432

Published: 2016

Journal Articles

Most Closely HLA-Matched Third Party Allogeneic CMV Specific T-Cells Generated Using the Cytokine Capture System for the Treatment of CMV Infections after Allogeneic Stem Cell Transplantation

Blood (2016) 128 (22): 4547.

https://doi.org/10.1182/blood.V128.22.4547.4547

Published: 2016

Journal Articles

Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant

Susan Prockop, MD, Ekaterina Doubrovina, MD PhD, Aisha N Hasan, MD, Parastoo B Dahi, MD, Sergio Giralt, MD, Guenther Koehne, MD PhD, Nancy A. Kernan, MD, Esperanza B Papadopoulos, MD, Rachel Lehrman, Irene Rodriguez-Sanchez, Richard J. O'Reilly, MD

Blood (2016) 128 (22): 61.

https://doi.org/10.1182/blood.V128.22.61.61

Published: 2016

NARROW

The Economic and Health Utilization Cost of Clinically Significant Cytomegalovirus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation

Efficacy of Artesunate for Treatment of Cytomegalovirus Reactivations in Allogeneic Haematopoietic Stem Cell Transplant Recipients Who Are Intolerant/Unsuitable for Ganciclovir Therapy

Increased Incidence of Viral Reactivation after T Cell Replete Haploidentical Stem Cell Transplantation in Association with Delayed Immune Reconstitution

The Efficacy and Safety of Cidofovir in Salvage Therapy for CMV Infection in the Patients with Haploid Hematopoietic Stem Cell Transplantation

Letermovir Prophylaxis Is Effective for Cytomegalovirus Reactivation after Allogeneic Hematopoietic Cell Transplantation: Single Center Real-World Data

ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience

Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function

A Step Forward Towards Cytomegalovirus Free Hematopoietic Stem Cell Transplantation

Post Transplant Prophylaxis with High Dose Valacyclovir through Day 100 Versus Day of Post Transplant Hospital Discharge Decreases Cytomegalovirus Reactivation in Adult Umbilical Cord Blood Transplant Recipients

Prospective Study of High Dose Foscarnet Prophylaxis for HHV-6 Related CNS Diseases in Cord Blood Transplantation for Adult Patients

CMV Reactivation Post CD34+ Selected Allo-HCT Has Adverse Outcomes on Blood Counts Recovery

BK Virus Induced Haemorrhagic Cystitis in Haematopoietic Stem Cell Transplant Setting — a 10 Year Retrospective Case Control Study

Use of Leflunomide for Treatment of Cytomegalovirus Infection in Recipients of Allogeneic Stem Cell Transplant

HHV-6 Prophylaxis with Foscanet Improves Hematopoietic Engraftment after Umbilical Cord Blood Transplantation

3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood

Analysis of Anti-CMV T-Cell Immunity and CMV Reactivation after Allogeneic Hematopoietic Cell Transplantation

Donor-Derived Marrow Mesenchymal Stem Cells Co-Transplantation Following Haploidentical Hematopoietic Stem Cell transplantation: a Multicenter Clinical Study in 35 Severe Aplastic Anemia Children

How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients

Most Closely HLA-Matched Third Party Allogeneic CMV Specific T-Cells Generated Using the Cytokine Capture System for the Treatment of CMV Infections after Allogeneic Stem Cell Transplantation

Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only